AsiaMedic 505
SGD 0.018
+0.00% +0.00 Updated 12 Nov 2026, 17:16 SGT
Financials
ASIAMEDIC LIMITED ANNUAL REPORT 2025
Explore the statements
8 tablesConsolidated Statement of Comprehensive Income
23 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2025Group | 2024Group | Source |
|---|---|---|---|
| Income | |||
| Revenue$ | 35,221,232 | 28,914,624 | PDF p. 51 |
| Other income$ | 1,698,244 | 663,895 | PDF p. 51 |
| Expenses | |||
| Consumables used$ | (2,111,418) | (2,048,035) | PDF p. 51 |
| Personnel expenses$ | (16,061,069) | (14,347,307) | PDF p. 51 |
| Depreciation of non-current assets | |||
| - Plant and equipment$ | (893,411) | (691,006) | PDF p. 51 |
| - Right-of-use assets$ | (2,489,380) | (1,777,378) | PDF p. 51 |
| Expenses | |||
| Maintenance expenses$ | (543,889) | (1,020,974) | PDF p. 51 |
| Laboratory and consultancy fees$ | (7,176,455) | (5,867,765) | PDF p. 51 |
| Facility and admin fees$ | (1,475,672) | (1,020,288) | PDF p. 51 |
| Finance costs$ | (912,577) | (565,201) | PDF p. 51 |
| Other operating expenses$ | (4,213,830) | (1,973,001) | PDF p. 51 |
| Impairment loss on financial assets, net - third party$ | (12,535) | – | PDF p. 51 |
| Receivables written off$ | – | (14,049) | PDF p. 51 |
| Income | |||
| Reversal of impairment loss of non-current assets, net$ | – | 71,704 | PDF p. 51 |
| Share of results of associates$ | 399,693 | 316,322 | PDF p. 51 |
| Profit | |||
| Profit before tax$ | 1,428,933 | 641,541 | PDF p. 51 |
| Income tax credit$ | – | 4,177 | PDF p. 51 |
| Profit for the financial year, representing total comprehensive income for the financial year$ | 1,428,933 | 645,718 | PDF p. 51 |
| Profit attributable to | |||
| Equity holders of the Company$ | 2,023,801 | 1,009,648 | PDF p. 51 |
| Non-controlling interests$ | (594,868) | (363,930) | PDF p. 51 |
| Subtotal$ | 1,428,933 | 645,718 | PDF p. 51 |
| Earnings per share for profit attributable to equity holders of the Company (cent per share) | |||
| Basiccent per share | 0.177 | 0.087 | PDF p. 51 |
| Dilutedcent per share | 0.175 | 0.087 | PDF p. 51 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 51 ↗
For the financial year ended 31 December 2025. No separate Company income statement is presented.
Balance Sheets as at 31 December 2025 (Group and Company)
33 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2025Group | 2024Group | 2025Company | 2024Company | Source |
|---|---|---|---|---|---|
| Non-current assets | |||||
| Plant and equipment$ | 4,168,083 | 3,818,584 | 25,185 | 41,854 | PDF p. 52 |
| Investment in subsidiaries$ | – | – | 8,409,804 | 8,409,804 | PDF p. 52 |
| Investment in associates$ | 2,449,878 | 2,199,062 | 181,500 | 181,500 | PDF p. 52 |
| Right-of-use assets$ | 18,707,585 | 22,137,444 | 3,745,671 | 4,758,699 | PDF p. 52 |
| Goodwill$ | – | – | – | – | PDF p. 52 |
| Deferred tax assets$ | 891,000 | 891,000 | – | – | PDF p. 52 |
| Subtotal$ | 26,216,546 | 29,046,090 | 12,362,160 | 13,391,857 | PDF p. 52 |
| Current assets | |||||
| Inventories$ | 142,425 | 315,279 | – | – | PDF p. 52 |
| Trade receivables$ | 4,802,838 | 4,078,065 | – | – | PDF p. 52 |
| Other receivables and deposits$ | 1,784,002 | 1,093,953 | 4,665,726 | 4,469,008 | PDF p. 52 |
| Prepayments$ | 260,138 | 267,734 | 48,229 | 38,603 | PDF p. 52 |
| Other financial assets$ | 3,991,907 | 3,486,109 | 3,991,907 | 3,486,109 | PDF p. 52 |
| Cash pledged as security$ | 295,920 | 475,920 | – | – | PDF p. 52 |
| Cash and cash equivalents$ | 5,694,448 | 7,991,497 | 741,004 | 1,128,134 | PDF p. 52 |
| Subtotal$ | 16,971,678 | 17,708,557 | 9,446,866 | 9,121,854 | PDF p. 52 |
| Current liabilities | |||||
| Trade payables$ | 1,370,607 | 1,640,452 | – | – | PDF p. 52 |
| Other payables and accruals$ | 3,448,112 | 4,765,615 | 3,038,164 | 4,751,549 | PDF p. 52 |
| Contract liabilities$ | 800,864 | 644,311 | – | – | PDF p. 52 |
| Borrowings$ | 2,450,477 | 2,354,572 | 989,983 | 1,027,072 | PDF p. 52 |
| Subtotal$ | 8,070,060 | 9,404,950 | 4,028,147 | 5,778,621 | PDF p. 52 |
| Net current assets$ | 8,901,618 | 8,303,607 | 5,418,719 | 3,343,233 | PDF p. 52 |
| Non-current liabilities | |||||
| Provision for reinstatement$ | 1,592,064 | 1,611,478 | 471,201 | 452,966 | PDF p. 52 |
| Borrowings$ | 15,415,737 | 18,797,613 | 3,376,470 | 4,366,450 | PDF p. 52 |
| Deferred tax liabilities$ | 16,065 | 18,391 | – | – | PDF p. 52 |
| Subtotal$ | 17,023,866 | 20,427,482 | 3,847,671 | 4,819,416 | PDF p. 52 |
| Net assets | |||||
| Net assets$ | 18,094,298 | 16,922,215 | 13,933,208 | 11,915,674 | PDF p. 52 |
| Equity attributable to equity holders of the Company | |||||
| Share capital$ | 33,394,437 | 33,669,437 | 33,394,437 | 33,669,437 | PDF p. 52 |
| Treasury shares$ | (2,866) | (2,866) | (2,866) | (2,866) | PDF p. 52 |
| Other reserves$ | 137,210 | (533,484) | 145,399 | 127,249 | PDF p. 52 |
| Accumulated losses$ | (17,475,685) | (18,846,942) | (19,603,762) | (21,878,146) | PDF p. 52 |
| Subtotal$ | 16,053,096 | 14,286,145 | 13,933,208 | 11,915,674 | PDF p. 52 |
| Equity | |||||
| Non-controlling interest$ | 2,041,202 | 2,636,070 | – | – | PDF p. 52 |
| Total equity$ | 18,094,298 | 16,922,215 | 13,933,208 | 11,915,674 | PDF p. 52 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 52 ↗
As at 31 December 2025. Note column omitted from values.
Consolidated Statement of Comprehensive Income
7 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, FY ended 31 December 2025, $ | 2024Group, FY ended 31 December 2024, $ | Source |
|---|---|---|---|
| Total comprehensive income | |||
| Profit for the financial year, representing total comprehensive income for the financial year$ | 1,428,933 | 645,718 | PDF p. 51 |
| Profit attributable to | |||
| Equity holders of the Company$ | 2,023,801 | 1,009,648 | PDF p. 51 |
| Non-controlling interests$ | (594,868) | (363,930) | PDF p. 51 |
| Income statement | |||
| Profit before tax$ | 1,428,933 | 641,541 | PDF p. 51 |
| Income tax credit$ | – | 4,177 | PDF p. 51 |
| Earnings per share (cent per share) | |||
| Basiccent per share | 0.177 | 0.087 | PDF p. 51 |
| Dilutedcent per share | 0.175 | 0.087 | PDF p. 51 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 51 ↗
No separate other comprehensive income items; profit represents total comprehensive income. Profit before tax shown for reference.
Consolidated Statement of Changes in Equity
10 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2025Share capital (Note 24), $ | 2025Other reserves (Note 26), $ | 2025Treasury shares (Note 25), $ | 2025Accumulated losses, $ | 2025Total attributable to equity holders of the Company, $ | 2025Non-controlling interest, $ | 2025Total equity, $ | Source |
|---|---|---|---|---|---|---|---|---|
| 2024 movements | ||||||||
| Balance at 1 January 2024$ | 33,669,437 | (553,449) | (2,866) | (19,856,590) | 13,256,532 | – | 13,256,532 | PDF p. 53 |
| Profit/(loss) for the financial year, representing total comprehensive income/ (loss) for the financial year (2024)$ | – | – | – | 1,009,648 | 1,009,648 | (363,930) | 645,718 | PDF p. 53 |
| Capital contribution from non-controlling interest$ | – | – | – | – | – | 3,000,000 | 3,000,000 | PDF p. 53 |
| Grant of equity-settled share options to employees (2024)$ | – | 19,965 | – | – | 19,965 | – | 19,965 | PDF p. 53 |
| Balance at 31 December 2024$ | 33,669,437 | (533,484) | (2,866) | (18,846,942) | 14,286,145 | 2,636,070 | 16,922,215 | PDF p. 53 |
| 2025 movements | ||||||||
| Profit/(loss) for the financial year, representing total comprehensive income/ (loss) for the financial year (2025)$ | – | – | – | 2,023,801 | 2,023,801 | (594,868) | 1,428,933 | PDF p. 53 |
| Capital reduction$ | (275,000) | – | – | – | (275,000) | – | (275,000) | PDF p. 53 |
| Grant of equity-settled share options to employees (2025)$ | – | 18,150 | – | – | 18,150 | – | 18,150 | PDF p. 53 |
| Reclassification (Note 26)$ | – | 652,544 | – | (652,544) | – | – | – | PDF p. 53 |
| Balance at 31 December 2025$ | 33,394,437 | 137,210 | (2,866) | (17,475,685) | 16,053,096 | 2,041,202 | 18,094,298 | PDF p. 53 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 53 ↗
Row labels wrap over lines in source; the Balance 31 December rows and profit rows begin on prior lines. Columns: Share capital, Other reserves, Treasury shares, Accumulated losses, Total, Non-controlling interest, Total equity. Rows are movements for FY2024 and FY2025.
Company Statement of Changes in Equity
8 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2025Company, Share capital (Note 24), $ | 2025Company, Other reserves (Note 26), $ | 2025Company, Treasury shares (Note 25), $ | 2025Company, Accumulated losses, $ | 2025Company, Total equity, $ | Source |
|---|---|---|---|---|---|---|
| 2024 movements | ||||||
| Balance at 1 January 2024$ | 33,669,437 | 107,284 | (2,866) | (23,463,115) | 10,310,740 | PDF p. 54 |
| Profit for the financial year, representing total comprehensive income for the financial year (2024)$ | – | – | – | 1,584,969 | 1,584,969 | PDF p. 54 |
| Grant of equity-settled share options to employees (2024)$ | – | 19,965 | – | – | 19,965 | PDF p. 54 |
| Balance at 31 December 2024$ | 33,669,437 | 127,249 | (2,866) | (21,878,146) | 11,915,674 | PDF p. 54 |
| 2025 movements | ||||||
| Profit for the financial year, representing total comprehensive income for the financial year (2025)$ | – | – | – | 2,274,384 | 2,274,384 | PDF p. 54 |
| Capital reduction$ | (275,000) | – | – | – | (275,000) | PDF p. 54 |
| Grant of equity-settled share options to employees (2025)$ | – | 18,150 | – | – | 18,150 | PDF p. 54 |
| Balance at 31 December 2025$ | 33,394,437 | 145,399 | (2,866) | (19,603,762) | 13,933,208 | PDF p. 54 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 54 ↗
Rows are movements for FY2024 and FY2025.
Consolidated Statement of Cash Flows
41 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, $ | 2024Group, $ | Source |
|---|---|---|---|
| Operating activities | |||
| Profit before tax$ | 1,428,933 | 641,541 | PDF p. 55 |
| Operating activities - Adjustments | |||
| Depreciation of plant and equipment$ | 893,411 | 691,006 | PDF p. 55 |
| Depreciation of right-of-use assets$ | 2,489,380 | 1,777,378 | PDF p. 55 |
| Reversal of impairment loss on right-of-use assets$ | – | (120,000) | PDF p. 55 |
| Impairment loss on goodwill$ | – | 48,296 | PDF p. 55 |
| Impairment loss on financial assets, net - third party$ | 12,535 | – | PDF p. 55 |
| Receivables written off$ | – | 14,049 | PDF p. 55 |
| Gain on modification of right-of-use assets$ | (6,337) | – | PDF p. 55 |
| Plant and equipment written off$ | 6,178 | – | PDF p. 55 |
| Gain on disposal of plant and equipment$ | (61,680) | – | PDF p. 55 |
| Loss on disposal of plant and equipment$ | 4,392 | – | PDF p. 55 |
| Finance costs$ | 912,577 | 565,201 | PDF p. 55 |
| Interest income$ | (114,019) | (170,439) | PDF p. 55 |
| Gain on disposal of shareholdings in previously-owned subsidiary$ | (879,511) | – | PDF p. 55 |
| Waiver of interest payable$ | (113,038) | – | PDF p. 55 |
| Grant of equity-settled share options to employees$ | 18,150 | 19,965 | PDF p. 55 |
| Amortisation of Employment Bond$ | – | 31,226 | PDF p. 55 |
| Share of results of associates$ | (399,693) | (316,322) | PDF p. 55 |
| Operating activities | |||
| Operating cash flows before changes in working capital$ | 4,191,278 | 3,181,901 | PDF p. 55 |
| Changes in working capital | |||
| Inventories$ | 56,646 | 48,226 | PDF p. 55 |
| Trade receivables, other receivables and deposits, and prepayments$ | (635,390) | (1,521,719) | PDF p. 55 |
| Trade payables and other payables and accruals$ | (304,345) | 991,233 | PDF p. 55 |
| Contract liabilities$ | 570,389 | (218,876) | PDF p. 55 |
| Operating activities | |||
| Net cash flows from operating activities$ | 3,878,578 | 2,480,765 | PDF p. 55 |
| Investing activities | |||
| Interest received$ | 114,019 | 172,734 | PDF p. 55 |
| Investment in associate$ | (40,000) | – | PDF p. 55 |
| Dividend received from associate$ | 266,477 | 360,085 | PDF p. 55 |
| (Addition in)/redemption of investments in other financial assets$ | (505,798) | 1,486,361 | PDF p. 55 |
| Net cash outflow arising from derecognition of previously-owned subsidiary$ | (211,181) | – | PDF p. 55 |
| Proceeds from disposal of plant and equipment$ | 71,835 | – | PDF p. 55 |
| Purchase of plant and equipment$ | (2,201,986) | (728,287) | PDF p. 55 |
| Purchase of medical equipment$ | (474,060) | (1,077,210) | PDF p. 55 |
| Net cash flows (used in)/from investing activities$ | (2,980,694) | 213,683 | PDF p. 55 |
| Financing activities | |||
| Decrease in cash pledged as security$ | – | 87,300 | PDF p. 55 |
| Contribution from non-controlling interest$ | – | 3,000,000 | PDF p. 55 |
| Interest paid$ | (883,973) | (587,193) | PDF p. 55 |
| Payment of principal portion of borrowings$ | (2,310,960) | (1,807,361) | PDF p. 55 |
| Net cash flows (used in)/from financing activities$ | (3,194,933) | 692,746 | PDF p. 55 |
| Net change in cash | |||
| Net (decrease)/increase in cash and cash equivalents$ | (2,297,049) | 3,387,194 | PDF p. 55 |
| Cash and cash equivalents at beginning of the financial year$ | 7,991,497 | 4,604,303 | PDF p. 55 |
| Cash and cash equivalents at 31 December$ | 5,694,448 | 7,991,497 | PDF p. 55 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 55 ↗
Only a consolidated (Group) cash flow statement is presented; no separate Company cash flow statement.
Earnings per share (Group) - Consolidated Statement of Comprehensive Income and Note 9
2 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, FY2025 | 2024Group, FY2024 | Source |
|---|---|---|---|
| Earnings per share (cent per share) | |||
| Basiccent per share | 0.177 | 0.087 | PDF p. 51 |
| Dilutedcent per share | 0.175 | 0.087 | PDF p. 51 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 51 ↗
Note 9 Earnings per share - basic and diluted computation (Group)
5 metricsUnits appear below each metric. Scroll to compare years
| Metric / unit | 2025Group, 2025 | 2024Group, 2024 | Source |
|---|---|---|---|
| Basic earnings per share | |||
| Profit for the financial year attributable to owners of the Company ($)$ | 2,023,801 | 1,009,648 | PDF p. 67 |
| Weighted average number of ordinary shares (excluding treasury shares) outstanding for basic earnings per sharenumber of shares | 1,140,412,681 | 1,154,522,270 | PDF p. 67 |
| Basic earnings per share (cent per share)cent per share | 0.177 | 0.087 | PDF p. 67 |
| Diluted earnings per share | |||
| Adjustment for 2023 share optionsnumber of shares | 14,705,882 | – | PDF p. 67 |
| Diluted earnings per share (cent per share)cent per share | 0.175 | 0.087 | PDF p. 67 |
No matching metrics in this statement. Try another term or clear the search.
Definitions & sources
Original report: PDF p. 67 ↗
Basic: profit attributable to owners divided by weighted average number of ordinary shares outstanding during the year. Diluted: adjusted for dilutive potential ordinary shares, which is the share options; diluted weighted shares 1,155,118,563 (2025) and 1,154,522,270 (2024).
Debt
Borrowings
Borrowing notes 1 tables
Borrowings
| Item / unit | 2025Group, $ | 2024Group, $ | 2025Company, $ | 2024Company, $ | Source |
|---|---|---|---|---|---|
| Current | |||||
| Hire-purchase loan (secured)$ | 807,672 | 481,116 | – | – | PDF p. 87 |
| Term loan$ | 187,000 | 204,000 | – | – | PDF p. 87 |
| Lease liabilities$ | 1,455,805 | 1,669,456 | 989,983 | 1,027,072 | PDF p. 87 |
| Total current$ | 2,450,477 | 2,354,572 | 989,983 | 1,027,072 | PDF p. 87 |
| Non-current | |||||
| Hire-purchase loan (secured)$ | 7,502,333 | 8,489,515 | – | – | PDF p. 87 |
| Term loan$ | – | 187,000 | – | – | PDF p. 87 |
| Lease liabilities$ | 7,913,404 | 10,121,098 | 3,376,470 | 4,366,450 | PDF p. 87 |
| Total non-current$ | 15,415,737 | 18,797,613 | 3,376,470 | 4,366,450 | PDF p. 87 |
| Total | |||||
| Total$ | 17,866,214 | 21,152,185 | 4,366,453 | 5,393,522 | PDF p. 87 |
Notes
Hire-purchase loan is secured by medical equipment with net carrying amount of $10,280,782 (2024: $11,222,805) (Note 28) and corporate guarantee by the Company.
The Company provided a corporate guarantee for the term loan.
Term loan is not labelled secured/unsecured in table; no interest rates or currency denomination found in pages read.
Payout
Dividends & distributions
Dividend policy
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Provision 11.6 Dividend | The Company has not adopted a formal dividend policy and the Board is responsible for the determination of dividend payments. Management may provide recommendations after taking into consideration the Group’s financial performance, cash flow position and capital requirements, but the final decision rests with the Board. | Company, FY2025 | PDF p. 39 |
Extracted from ASIAMEDIC LIMITED ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
Auditor’s report
Audit & risk signals
Audit opinion
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Audit firm | Baker Tilly TFW LLP | Group and Company, FY2025 | PDF p. 50 |
| Engagement partner | Gilbert Lee Chee Sum | Group and Company, FY2025 | PDF p. 50 |
| Opinion | properly drawn up in accordance with the provisions of the Companies Act 1967 | Group and Company, FY2025 | PDF p. 47 |
Key audit matters
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Impairment assessment on plant and equipment and right-of-use assets | Management’s assessment of the recoverable amounts is significant to our audit due to the magnitude of the carrying amounts of the assets being tested for impairment and the key assumptions and estimates used in determination of the recoverable amounts. | Group, FY2025 | PDF p. 47 |
Extracted from ASIAMEDIC LIMITED ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
How to read these figures
Group and parent company or bank figures are labelled separately. Parentheses indicate negative amounts; a dash and NA retain the report’s notation.
Comparative figures follow ASIAMEDIC LIMITED ANNUAL REPORT 2025, including retrospective adjustments. Adjusted and reported earnings may have different definitions; refer to each statement’s notes.
These tables show the available extracted figures. The original annual report contains the full statements, notes and definitions.